Not available
Quote | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Last: | $23.39 |
---|---|
Change Percent: | -0.69% |
Open: | $23.24 |
Close: | $23.39 |
High: | $23.62 |
Low: | $23.2 |
Volume: | 576,086 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-21 05:50:25 ET Summary Syndax Pharmaceuticals has upcoming Q3 PDUFAs for revumenib and axatilimab, both awarded priority review. Syndax pegs both upcoming PDUFAs as potential blockbusters once approved, with revumenib offering a larger revenue opportunity. Syndax's val...
Message Board Posts | Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION! $SNDX $STRO $MTEM $KRYS Clinical-Stage | AviseAnalytics | investorshangout | 10/05/2021 12:45:05 PM |
Nice rebound today for $SNDX, beat the street | dealerschool2006 | investorshub | 05/12/2021 8:13:51 PM |
$SNDX recovering from panic sale!!! | dealerschool2006 | investorshub | 04/28/2021 4:46:26 PM |
Panic sale for SNDX on positive results...May options | dealerschool2006 | investorshub | 04/20/2021 2:52:48 PM |
Its interesting how a company such as this | DaytraderJohn | investorshub | 04/29/2020 6:39:33 AM |
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...